Superstructure-based process synthesis and economic assessment under uncertainty for solid drug product manufacturing

IF 2.35
Kensaku Matsunami, Fabian Sternal, Keita Yaginuma, Shuichi Tanabe, Hiroshi Nakagawa, Hirokazu Sugiyama
{"title":"Superstructure-based process synthesis and economic assessment under uncertainty for solid drug product manufacturing","authors":"Kensaku Matsunami,&nbsp;Fabian Sternal,&nbsp;Keita Yaginuma,&nbsp;Shuichi Tanabe,&nbsp;Hiroshi Nakagawa,&nbsp;Hirokazu Sugiyama","doi":"10.1186/s42480-020-0028-2","DOIUrl":null,"url":null,"abstract":"<p>This paper presents a new method for process synthesis and economic assessment for solid drug product manufacturing, considering continuous manufacturing as a prominent process alternative. Of the three phases of drug development, phase II was targeted where the dosage form, formulation, and processing technology are determined. For a comprehensive alternative generation, a superstructure was developed that covered 9452 options for the unit level, which was combined with two options on the formulation strategy. The generated alternative was assessed by a net present value calculation model, which was adapted for dynamic cash flow consideration in the drug lifecycle. The model can incorporate uncertainty in the drug development and manufacturing in the result, and can perform global sensitivity analysis by Monte Carlo simulation. The method was demonstrated in a case study where two different scenarios regarding the price of the active pharmaceutical ingredient and the demand for the product were assumed. The results showed that when the demand and price are both low, the labor-related costs are dominant, and in the opposite case, the material-related costs become relevant. We also introduce the prototype version of the software “SoliDecision,” by which the presented method was implemented for industrial application.</p>","PeriodicalId":495,"journal":{"name":"BMC Chemical Engineering","volume":"2 1","pages":""},"PeriodicalIF":2.3500,"publicationDate":"2020-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s42480-020-0028-2","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Chemical Engineering","FirstCategoryId":"5","ListUrlMain":"https://link.springer.com/article/10.1186/s42480-020-0028-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11

Abstract

This paper presents a new method for process synthesis and economic assessment for solid drug product manufacturing, considering continuous manufacturing as a prominent process alternative. Of the three phases of drug development, phase II was targeted where the dosage form, formulation, and processing technology are determined. For a comprehensive alternative generation, a superstructure was developed that covered 9452 options for the unit level, which was combined with two options on the formulation strategy. The generated alternative was assessed by a net present value calculation model, which was adapted for dynamic cash flow consideration in the drug lifecycle. The model can incorporate uncertainty in the drug development and manufacturing in the result, and can perform global sensitivity analysis by Monte Carlo simulation. The method was demonstrated in a case study where two different scenarios regarding the price of the active pharmaceutical ingredient and the demand for the product were assumed. The results showed that when the demand and price are both low, the labor-related costs are dominant, and in the opposite case, the material-related costs become relevant. We also introduce the prototype version of the software “SoliDecision,” by which the presented method was implemented for industrial application.

Abstract Image

固体药品生产中基于上层结构的工艺综合及不确定条件下的经济评价
本文提出了一种固体药品生产工艺合成和经济评价的新方法,认为连续生产是一种突出的工艺选择。在药物开发的三个阶段中,第二阶段是确定剂型、配方和加工技术的目标阶段。对于一个全面的替代一代,开发了一个上层建筑,涵盖了9452个单元级别的选项,并结合了两个制定策略的选项。生成的替代方案通过净现值计算模型进行评估,该模型适用于药物生命周期中的动态现金流量考虑。该模型能将药物开发和生产过程中的不确定性纳入结果,并能通过蒙特卡罗仿真进行全局敏感性分析。该方法在一个案例研究中得到了证明,该案例研究假设了活性药物成分的价格和产品需求的两种不同情况。结果表明,当需求和价格都较低时,人工相关成本占主导地位,反之,材料相关成本占主导地位。我们还介绍了软件“SoliDecision”的原型版本,通过它实现了所提出的方法用于工业应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信